Clinical Trials

07 Sep 2020
- Clinical Trials
- Human Trials
Novartis says high-dose Enerzair Breezhaler reduces asthma exacerbations versus medium-dose

By PBR Staff Writer

Novartis announced that high-dose, once-daily Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) significantly reduces both moderate-or-severe and severe asthma exacerbation rates in patients whose asthma is uncontrolled on medium- or high-dose long-acting beta2-agonist (LABA)/inhaled corticosteroids (ICS), when compared with a once-daily medium-dose of the same treatment.
07 Sep 2020
Clinical Trials
Patient Enrollment
Ampio announces enrolment completion for intravenous Covid-19 clinical trial

By PBR Staff Writer

Ampio Pharmaceuticals, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions announces the following:
07 Sep 2020
Drug Discovery
Clinical Trials
InPro 8000 Series Turbidity Sensor

By victoria.smith

This fiber optic measuring system is based on the backscattered light principle and consequently provides the highest possible performance from low/medium turbidities right through to high suspended particle concentrations.
04 Sep 2020
Clinical Trials
Human Trials
Octapharma launches phase 3 superiority study for PANS

By PBR Staff Writer

Octapharma has launched a phase 3, multicenter superiority study to compare the effectiveness of PANZYGA (immune globulin intravenous, human - ifas) 10% Liquid Preparation versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome (PANS).
03 Sep 2020
Clinical Trials
Human Trials
PharmaCyte Biotech submits IND to FDA for clinical trial in inoperable pancreatic cancer

By PBR Staff Writer

PharmaCyte Biotech has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for a planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).
03 Sep 2020
Clinical Trials
Human Trials
Twist Bioscience announces potent SARS-CoV-2 neutralising data from Covid-19 therapeutic antibody programme

By PBR Staff Writer

Twist Bioscience announced data demonstrating the potent neutralizing effects of multiple potential therapeutic antibodies, both Immunoglobulin G (IgG) antibodies and substantially smaller single domain VHH “nanobodies,” against SARS-CoV-2, the virus that causes Covid-19.
03 Sep 2020
Clinical Trials
Human Trials
Sanofi, GSK begin phase 1/2 clinical trial of Covid-19 vaccine candidate

By PBR Staff Writer

French pharmaceutical firm Sanofi and British drugmaker GlaxoSmithKline (GSK) have commenced the phase 1/2 clinical of the Covid-19 adjuvanted recombinant protein-based vaccine candidate.
02 Sep 2020
Clinical Trials
Patient Enrollment
Clear Creek Bio doses first patient in Covid-19 trial with brequinar

By PBR Staff Writer

Clear Creek Bio has dosed the first patient in phase 1 clinical study of brequinar in hospitalised patients with Covid-19.
01 Sep 2020
Clinical Trials
Human Trials
Vir, GSK begin phase 2/3 trial of VIR-7831 as Covid-19 antibody treatment

By PBR Staff Writer

Vir Biotechnology and GlaxoSmithKline (GSK) have started a phase 2/3 study of VIR-7831 (also known as GSK4182136) as a Covid-19 antibody treatment by dosing the first patient.
01 Sep 2020
Clinical Trials
Patient Enrollment
Orpheris enrols first patients in phase 2 clinical study evaluating OP-101 for severe Covid-19

By PBR Staff Writer

Orpheris, a wholly-owned subsidiary of Ashvattha Therapeutics, a biotech company focused on developing novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in inflammatory, oncology and ocular diseases, today announced enrollment of the first patients in its multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hospitalized adults with severe Covid-19.

Drug Discovery

Research & Development

Superluminal Medicines secures $60m to advance rare obesity therapy

Takeda and Weave Bio collaborate on AI-driven automation in drug development

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG

Gerresheimer at CPHI Frankfurt 2025

Suppliers

No data found

Clinical Trials

Novartis says high-dose Enerzair Breezhaler reduces asthma exacerbations versus medium-dose

Ampio announces enrolment completion for intravenous Covid-19 clinical trial

InPro 8000 Series Turbidity Sensor

Octapharma launches phase 3 superiority study for PANS

PharmaCyte Biotech submits IND to FDA for clinical trial in inoperable pancreatic cancer

Twist Bioscience announces potent SARS-CoV-2 neutralising data from Covid-19 therapeutic antibody programme

Sanofi, GSK begin phase 1/2 clinical trial of Covid-19 vaccine candidate

Clear Creek Bio doses first patient in Covid-19 trial with brequinar

Vir, GSK begin phase 2/3 trial of VIR-7831 as Covid-19 antibody treatment

Orpheris enrols first patients in phase 2 clinical study evaluating OP-101 for severe Covid-19

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found